

29th February, 2024

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,


Sub: Outcome of the Board Meeting held on February 29,2024.

Ref: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 (read with Part A of Schedule III) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, this is to inform you that the Board of Directors at its meeting held today i.e. February 29, 2024, has inter-alia, considered and approved the following items:

1. Issue of Bonus Shares in the proportion of 3: 1 i.e. 3 (Three) fully paid-up bonus equity share of Rs. 10/- (Rupees Ten only) each for every 1 (One) fully paid-up equity share of Rs. 10/- (Rupees Ten only) each held by the Members of the Company as on the Record Date, subject to approval of Members of the Company through Postal Ballot.
2. Increase in Authorize share capital of the company from 12,00,00,000/- (Rupees Twelve Crore to 44,00,00,000/- (Rupees Forty-four Crore) by altering the capital clause of Memorandum of Association of the company subject to approval of Members of the company through Postal Ballot.
3. To amend the Article 38(ii)(d) of Article of Association of the company by altering the capital clause of Article of Association of the company subject to approval of Members of the company through Postal Ballot.
4. To approve the revision in remuneration of Mr. Dakshesh Shah, Chairman Cum Managing Director of the company.
5. Approved postal ballot notice for seeking consent of Members of the Company for the Resolutions as set out in the postal ballot Notice and other matters incidental thereto.

CIN : L24231GJ1993PLC019079





SHUKRA

PHARMACEUTICALS LTD.

6. Appointment of Mrs. Rupal Patel, Practicing Company Secretary as 'Scrutinizer' to scrutinize the Postal Ballot process in a fair and transparent manner.

The detailed disclosure as required under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as Annexure-A.



The Board Meeting commenced at 03:00 PM and concluded at 04:35 PM we request you to take the same on record.

Kindly place the same on your record

Thanking you,


Yours faithfully

For Shukra Pharmaceuticals Limited

Arpita Kabra



Arpita Kabra
Company secretary – Compliance officer
ACS No. – A50258

CIN : L24231GJ1993PLC019079




Annexure-A


The detailed disclosure as required under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Issuance of Securities

Sr. NO	Particulars	Details
1.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Equity Shares
2	Type of Issuance (further public offering, rights issue, depository receipts (ADR /GDR), qualified institutions placement, preferential allotment etc.);	Bonus Shares
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	32,84,09,580/- (Rupees Thirty-Two Crore Eighty-Four Lakhs Nine Thousand and Five Hundred and Eighty Only)
4.	Whether bonus is out of free reserves created out of profits or share premium account	Bonus Equity shares will be issued out of credit of the Reserve and surplus account, Security premium account, Capital reserve and General Reserve available on the basis of financial statements as at 31 st December, 2023.
5.	Bonus ratio	3(three) equity shares for Every 1(One) equity share.
6.	Details of share capital - pre and post bonus issue	Pre-Bonus paid-up share capital: 10946986 shares having paid-up of Rs. 10 each per share. Post-Bonus paid-up share capital: 43787944 shares having paid-up value of Rs. 10 each per share.
7.	Free reserves and/ or share premium required for implementing the bonus issue	32,84,09,580/- (Rupees Thirty-Two Crore Eighty-



CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

			Four Lakhs Nine Thousand and Five Hundred and Eighty Only)
8.		Free reserves and/ or share premium available for capitalization and the date as on which such balance is available	386910809/- (rupees Thirty-eight crore sixty-nine lakh ten thousand eight hundred and nine.)
9.		Whether the aforesaid figures are audited	NO, the aforesaid figures are un- audited
10.		Estimated date by which bonus shares would be credited/ dispatched	Within 2 months from the date of Board.



CIN : L24231GJ1993PLC019079